HHS 503A discretion compound-by-compound: six peptides, six caveats
The October 2026 HHS enforcement-discretion policy for 503A compounding did not approve six research peptides. It named them. That distinction is already being flattened in marketing copy and social threads. This guide walks compound-by-compound through BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon/Epithalon: why each appeared on Appendix A after the July PCAC votes, what conditions still gate any compounding narrative, and what remains unchanged in FDA approval status, 503B practice, and foreign enforcement. Read it as a status map—not a green light.
The policy in one paragraph
HHS published an enforcement-discretion policy (Federal Register Doc. 2026-22192) stating that, while FDA continues 503A bulks-list rulemaking, HHS does not intend to take enforcement action against qualifying state-licensed pharmacies, federal facilities, or licensed physicians who compound listed peptide bulk drug substances under stated conditions. Compounded drugs remain unapproved. The policy is not a final addition to 21 CFR 216.23 and is not a 503B pathway.
BPC-157
BPC-157 received a narrow PCAC majority recommendation in July 2026 despite FDA staff concerns about limited human evidence and theoretical risk signals. Under the HHS policy it appears on Appendix A with route/identity limits described in policy materials. It is still not an FDA-approved drug for musculoskeletal or gut indications marketed in grey-market copy. Human evidence remains early (small pilots; larger RCTs recruiting). Discretion ≠ approval.
TB-500
TB-500 is commonly sold as a synthetic fragment related to thymosin beta-4 research—not identical to full-length Tβ4 drug candidates that reached ophthalmic and other trials. PCAC recommended it alongside BPC-157 for 503A list consideration. Appendix A inclusion under HHS discretion still requires the policy’s quality and prescription conditions. WADA and sport-testing contexts treat related thymosin pathways as prohibited in competition settings; researchers should keep sport and compounding frameworks separate.
KPV
KPV is an anti-inflammatory tripeptide fragment studied primarily in gut and barrier models. It was among the July PCAC “yes” votes and appears on the HHS six-peptide list. Mechanistic literature is stronger than large clinical outcomes literature. Educational use should emphasize preclinical weight of evidence and the absence of an FDA-approved KPV product.
MOTS-c
MOTS-c is a mitochondrial-derived peptide researched for metabolic and exercise-mimetic endpoints. PCAC recommended it; HHS listed it. Human trial programs exist but MOTS-c is not approved as a metabolic drug. Stacks that pair MOTS-c with SS-31 or NAD+ (as on this site’s Mito Stack materials) are research constructions, not labeled combination products.
Semax
Semax is a synthetic ACTH(4–10) analog studied for cognitive and neuroprotection endpoints, often as an intranasal research preparation. PCAC recommended it; HHS listed it with formulation constraints in policy appendices. It is not an FDA-approved neurology drug in the United States.
Epitalon (Epithalon)
Epitalon/Epithalon is a synthetic tetrapeptide associated with telomere and pineal research narratives that often outrun controlled human evidence. PCAC recommended it; HHS listed it. Longevity marketing claims should be separated from the narrow legal meaning of interim 503A discretion.
What still does not change
None of the six becomes FDA-approved by this notice. DSIP (emideltide), which PCAC did not recommend, is not on Appendix A. 503B outsourcing-facility bulk production is outside the policy’s core framing. Foreign regulators (TGA, MHRA, Swissmedic, and others) are not bound by HHS discretion. Grey-market “research chem” distribution remains a separate enforcement problem.
Editorial Note: This article is published for research and educational purposes only. Peptide Hub does not sell peptides, receive commissions from peptide vendors, or endorse any specific supplier. All compounds discussed are research peptides not approved for human therapeutic use except where specifically noted. This is not medical advice.